DAB2IP and triple-A syndrome: If, at a molecular level, the link between genetic variation at this locus, DAB2IP expression, and vascular disease was uncovered, enzymes such as EZH2 could also be potential novel targets in pharmacological therapies to attenuate AAA formation.